Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target

Author(s): A. Zaniboni and F. Meriggi

Volume 3 , Issue 8 , 2006

Page: [541 - 543] Pages: 3

DOI: 10.2174/157018006778194673

Price: $65

Abstract

The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable. The search for a reliable marker that would allow clinicians to select patients for cetuximab therapy remains a major challenge.

Keywords: Cetuximab, Colorectal cancer, Anti-EGFR therapy


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy